Osteopathic Center
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
Miami, FL
Stem cell and cell-based therapy in Miami is a closely watched regulatory space. FDA-approved stem cell products (hematopoietic, select cord blood) are delivered at academic centers tied to Jackson Health System, Baptist Health, and University of Miami Health. The vast majority of cash-pay stem cell offerings, mesenchymal, adipose-derived, amniotic, exosomes, are not FDA approved. Demand reflects a large international, Latin American, and aesthetic-focused patient base.
The FDA has aggressively pursued clinics marketing unapproved stem cell products for orthopedic, neurologic, and autoimmune indications. Clinics in Miami, Florida operating in this space should be evaluated carefully for informed consent, product sourcing, and honest evidence framing. Florida Department of Health oversight of office-based surgery and stem cell claims shapes enforcement posture.
With stem cell clinics on Regenerated.com in Miami, patients can compare product type, FDA status, clinician credentials, and whether the clinic is enrolling in registered trials or operating outside them.
Regulatory context
Florida cellular therapy providers are governed by 21 CFR Part 1271. Section 361 applies to minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 applies to products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND or BLA. Most stem cell, stromal vascular fraction, exosome, umbilical cord blood derived, and culture-expanded mesenchymal cell therapies marketed in Florida for orthopedic, neurologic, autoimmune, and longevity indications fall under Section 351 and lack FDA approval. Florida is a high-volume market, which has translated into elevated federal scrutiny.
Florida has been a primary target of FDA enforcement. In US v US Stem Cell Inc (2019), a federal court in Florida granted a permanent injunction against a Sunrise-based clinic for marketing unapproved stem cell products derived from adipose tissue. The Eleventh Circuit upheld the injunction in 2021. The FDA has issued multiple warning letters to Florida clinics offering exosome and umbilical cord-derived therapies. The Florida Department of Health and the Boards of Medicine and Osteopathic Medicine have disciplined physicians for unprofessional conduct tied to misleading regenerative medicine marketing. The Florida Attorney General has pursued deceptive trade practice claims under FDUTPA against stem cell clinics.